Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).

Approximately 129 NSCLC patients with metastatic disease were enrolled in the trial, all of whom had previously been treated with up to 5 lines of prior therapy. The patients were randomized to 3 different doses of nivolumab, given once every 2 weeks for up to 2 years.

The estimated 5-year overall survival (OS) for this group of patients was 16%. This is an improvement from historical data, Brahmer explains, which showed a 5-year OS of approximately 4% in patients who were treated for metastatic disease with standard treatment.